Scilex Holding Company Unveils Promising Phase 3 Trial Results and Strategic Advances in Pain Management and Gout Treatment’
Scilex Holding Company Accelerates Non-Opioid Therapeutic Innovations’
PALO ALTO, Calif. June 14, 2024’ Scilex Holding Company (Nasdaq: SCLX), a forward-thinking, revenue-generating firm specializing in the acquisition, development, and commercialization of non-opioid pain management solutions for both acute and chronic pain, has recently announced significant developments across its product portfolio. These advances include critical Phase 3 results for its novel pain management drug SP-102 (SEMDEXA), the FDA approval for commercial manufacturing of Gloperba, and a landmark settlement agreement with Takeda Pharmaceuticals regarding its FDA-approved liquid colchicine product.
Promising Phase 3 Results for SP-102 (SEMDEXA) Published in PAIN Journal’
Scilex Holding Company has proudly announced that the results of the pivotal Phase 3 registration trial of SP-102 (SEMDEXA) for lumbosacral radicular pain, commonly known as sciatica, have been prominently published in the prestigious PAIN journal. This journal is the official publication of the International Association for the Study of Pain and is renowned for disseminating original research on the nature, mechanisms, and treatment of pain.
The Phase 3 trial demonstrated that SP-102 (SEMDEXA) offers a significant improvement in pain relief for patients suffering from sciatica. As a non-opioid pain management option, SP-102 (SEMDEXA) aligns with the company’s mission to provide innovative pain relief solutions without the risks associated with opioid medications. These compelling results underscore Scilex’s commitment to addressing the unmet needs in pain management and enhancing the quality of life for patients.
FDA Approval and Launch of Gloperba’
Adding to its recent milestones, Scilex Holding Company has secured FDA approval for the commercial manufacturing of Gloperba, an FDA-approved prophylactic treatment for painful gout flares in adults. This approval marks a significant step forward in making the treatment widely available across the United States. Scilex has announced that Gloperba will be stocked in all major wholesalers and pharmacies starting June 10, 2024.
Gloperba’s commercial availability in the U.S. is expected to provide substantial relief for adult patients suffering from gout, a condition characterized by sudden and severe attacks of pain, swelling, and redness in the joints. With this launch, Scilex aims to solidify its position in the market for non-opioid treatments for painful conditions.
Resolution of Patent Infringement Lawsuit with Takeda Pharmaceuticals’
In a strategic legal development, Scilex Holding Company has also announced the final court approval of a settlement agreement with Takeda Pharmaceuticals. This agreement resolves a Paragraph IV patent infringement lawsuit related to Scilex’s intent to expand the label for its liquid colchicine product, Gloperba. The U.S. District Court for the District of Delaware entered a Consent Judgment on May 3, 2024, approving the settlement agreement after a 45-day review period by the U.S. Federal Trade Commission and U.S. Department of Justice expired without objection.
The settlement agreement includes a license agreement with Takeda, granting Scilex and its affiliates a non-exclusive license to certain patents owned by Takeda. Although the specific terms of these agreements remain confidential, this resolution enables Scilex to move forward with its plans to expand the label for Gloperba and potentially increase its market reach and impact.
A Unified Vision for Pain Management and Patient Care’
These recent developments reflect Scilex Holding Company’s commitment to expanding its portfolio of non-opioid pain management solutions and enhancing patient care across multiple therapeutic areas. The publication of promising Phase 3 trial results for SP-102 (SEMDEXA) and the commercial launch of Gloperba demonstrate the company’s dedication to innovation, efficacy, and patient safety.
As Scilex continues to forge strategic partnerships, secure regulatory approvals, and expand its product offerings, it remains at the forefront of non-opioid pain management, poised to make significant contributions to the healthcare industry and improve the lives of patients suffering from chronic pain and gout.
Comments